Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 13/20 | 0.64 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118090 | 0.96 | GRPR (0.60) | GRPRGLP1R | |
| SCHEMBL29663974 | 0.95 | GRPR (0.68) | GRPRGLP1R | |
| SCHEMBL31738530 | 0.94 | GRPR (0.64) | GRPR | |
| SCHEMBL20764506 | 0.94 | GRPR (0.59) | GRPRGLP1R | |
| SCHEMBL38660507 | 0.93 | GRPR (0.58) | GRPRGLP1R | |
| SCHEMBL38661265 | 0.93 | GRPR (0.65) | GRPRGLP1R | |
| SCHEMBL31223150 | 0.92 | GRPR (0.61) | GRPRGLP1R | |
| SCHEMBL30118066 | 0.92 | GRPR (0.61) | GRPRGLP1R | |
| SCHEMBL30628996 | 0.92 | GRPR (0.62) | GRPRGLP1R | |
| SCHEMBL4352525 | 0.91 | GRPR (0.67) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | disclosed |
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-11 | — | — | US | disclosed |
| EP-4499663-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2025-02-05 | — | — | EP | disclosed |
| CN-119213011-A | Radiolabeled compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2024-12-27 | — | — | CN | disclosed |
| US-20240123099-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-04-18 | — | — | US | disclosed |
| WO-2023178449-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246076-B2 | Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders | GRPR, NPY5R, NPY2R | GRPR 1/4885GLP1R 15/4885 |
| US-20240123099-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | GRPR 1/4885GLP1R 15/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | GRPR 1/4885GLP1R 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.